In this subpart:
The term “affiliate” means a business entity that has a relationship with a second business entity if, directly or indirectly—
one business entity controls, or has the power to control, the other business entity; or
a third party controls, or has power to control, both of the business entities.
The term “contract manufacturing organization facility” means an OTC monograph drug facility where neither the owner of such manufacturing facility nor any affiliate of such owner or facility sells the OTC monograph drug produced at such facility directly to wholesalers, retailers, or consumers in the United States.
The term “costs of resources allocated for OTC monograph drug activities” means the expenses in connection with OTC monograph drug activities for—
officers and employees of the Food and Drug Administration, contractors of the Food and Drug Administration, advisory committees, and costs related to such officers, employees, and committees and costs related to contracts with such contractors;
management of information, and the acquisition, maintenance, and repair of computer resources;
leasing, maintenance, renovation, and repair of facilities and acquisition, maintenance, and repair of fixtures, furniture, scientific equipment, and other necessary materials and supplies; and
section 379j–72 of this title collecting fees under and accounting for resources allocated for OTC monograph drug activities.
The term “FDA establishment identifier” is the unique number automatically generated by Food and Drug Administration’s Field Accomplishments and Compliance Tracking System (FACTS) (or any successor system).
section 355h of this title The term “OTC monograph drug” means a nonprescription drug without an approved new drug application which is governed by the provisions of .
The term “OTC monograph drug activities” means activities of the Secretary associated with OTC monograph drugs and inspection of facilities associated with such products, including the following activities:
The activities necessary for review and evaluation of OTC monographs and OTC monograph order requests, including—
orders proposing or finalizing applicable conditions of use for OTC monograph drugs;
orders affecting status regarding general recognition of safety and effectiveness of an OTC monograph ingredient or combination of ingredients under specified conditions of use;
all OTC monograph drug development and review activities, including intra-agency collaboration;
regulation and policy development activities related to OTC monograph drugs;
development of product standards for products subject to review and evaluation;
section 355h(i) of this title meetings referred to in ;
review of labeling prior to issuance of orders related to OTC monograph drugs or conditions of use; and
regulatory science activities related to OTC monograph drugs.
Inspections related to OTC monograph drugs.
Monitoring of clinical and other research conducted in connection with OTC monograph drugs.
Safety activities with respect to OTC monograph drugs, including—
collecting, developing, and reviewing safety information on OTC monograph drugs, including adverse event reports;
developing and using improved adverse event data-collection systems, including information technology systems; and
developing and using improved analytical tools to assess potential safety risks, including access to external databases.
section 355h of this title Other activities necessary for implementation of .
section 355h(b)(5) of this title The term “OTC monograph order request” means a request for an order submitted under .
The term “Tier 1 OTC monograph order request” means any OTC monograph order request not determined to be a Tier 2 OTC monograph order request.
The term “Tier 2 OTC monograph order request” means, subject to subparagraph (B), an OTC monograph order request for—
the reordering of existing information in the drug facts label of an OTC monograph drug;
the addition of information to the other information section of the drug facts label of an OTC monograph drug, as limited by section 201.66(c)(7) of title 21, Code of Federal Regulations (or any successor regulations);
section 355h(c)(3)(A) of this title modification to the directions for use section of the drug facts label of an OTC monograph drug, if such changes conform to changes made pursuant to ;
the standardization of the concentration or dose of a specific finalized ingredient within a particular finalized monograph;
a change to ingredient nomenclature to align with nomenclature of a standards-setting organization;
the addition of an interchangeable term in accordance with section 330.1 of title 21, Code of Federal Regulations (or any successor regulations); or
the addition or modification of a testing procedure applicable to one or more OTC monograph drugs, provided that such additional or modified testing procedure reflects a voluntary consensus standard with respect to pharmaceutical quality that is—
established by a national or international standards development organization; and
recognized by the Secretary through a process described in guidance for industry, initially published in July 2023, or any successor guidance, publicly available on the website of the Food and Drug Administration, which addresses voluntary consensus standards for pharmaceutical quality.
section 355h of this title The Secretary may, based on program implementation experience or other factors found appropriate by the Secretary, characterize any OTC monograph order request as a Tier 2 OTC monograph order request (including recharacterizing a request from Tier 1 to Tier 2) and publish such determination in a proposed order issued pursuant to .
The term “OTC monograph drug facility” means a foreign or domestic business or other entity that—
is—
under one management, either direct or indirect; and
at one geographic location or address engaged in manufacturing or processing the finished dosage form of an OTC monograph drug;
includes a finished dosage form manufacturer facility in a contractual relationship with the sponsor of one or more OTC monograph drugs to manufacture or process such drugs; and
does not include a business or other entity whose only manufacturing or processing activities are one or more of the following: production of clinical research supplies, testing, or placement of outer packaging on packages containing multiple products, for such purposes as creating multipacks, when each monograph drug product contained within the overpackaging is already in a final packaged form prior to placement in the outer overpackaging.
For purposes of subparagraph (A)(i)(II), separate buildings or locations within close proximity are considered to be at one geographic location or address if the activities conducted in such buildings or locations are—
closely related to the same business enterprise;
under the supervision of the same local management; and
under a single FDA establishment identifier and capable of being inspected by the Food and Drug Administration during a single inspection.
If a business or other entity would meet criteria specified in subparagraph (A), but for being under multiple management, the business or other entity is deemed to constitute multiple facilities, one per management entity, for purposes of this paragraph.
The term “OTC monograph drug meeting” means any meeting regarding the content of a proposed OTC monograph order request.
The term “person” includes an affiliate of a person.
section 355h of this title The terms “requestor” and “sponsor” have the meanings given such terms in .
June 25, 1938, ch. 675, § 744LPub. L. 116–136, div. A, title III, § 3862134 Stat. 459Pub. L. 119–37, div. F, title V, § 6503139 Stat. 637(, as added , , ; amended , , .)
Termination of Section
section 6509(a) of Pub. L. 119–37For termination of section by , see Termination Date note below.
Editorial Notes
Amendments
Pub. L. 119–37, § 6503(2)(A)2025—Par. (9)(A)(vi). , substituted “the addition” for “addition”.
Pub. L. 119–37, § 6503(1)Par. (9)(A)(vii). , (2)(B), (3), added cl. (vii)
Statutory Notes and Related Subsidiaries
Effective Date of 2025 Amendment
Pub. L. 119–37section 6510 of Pub. L. 119–37section 355 of this titleAmendment by effective , with fees under this subpart to be assessed beginning , see , set out as a note under .
Termination Date
Pub. L. 119–37, div. F, title V, § 6509(a)139 Stat. 648
21 U.S.C. 379j–71“Sections 744L and 744M of the Federal Food, Drug, and Cosmetic Act (; 379j–72) shall cease to be effective .”
, , , provided that:
Savings Clause
Pub. L. 119–37, div. F, title V, § 6511139 Stat. 648
21 U.S.C. 379j–71“Notwithstanding the amendments made by this title [amending this section and sections 355, 355h, 379j–72, and 379j–73 of this title], part 10 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act ( et seq.), as in effect on the day before the date of enactment of this Act [], shall continue to be in effect with respect to assessing and collecting any fee required by such part for a fiscal year prior to fiscal year 2026.”
, , , provided that:
Finding
Pub. L. 119–37, div. F, title V, § 6502139 Stat. 637
21 U.S.C. 379j–71“Congress finds that the fees authorized by the amendments made in this title [amending this section and sections 355, 355h, 379j–72, and 379j–73 of this title] will be dedicated to over-the-counter (OTC) monograph drug activities, as set forth in the goals identified for purposes of part 10 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act ( et seq.), in the letters from the Secretary of Health and Human Services to the Chairman of the Committee on Energy and Commerce of the House of Representatives and the Chairman of the Committee on Health, Education, Labor, and Pensions of the Senate, as set forth in the Congressional Record.”
, , , provided that:
Pub. L. 116–136, div. A, title III, § 3861134 Stat. 458
Pub. L. 116–136“The Congress finds that the fees authorized by the amendments made in this part [part II of subtitle F of title III of div. A of , enacting this subpart] will be dedicated to OTC monograph drug activities, as set forth in the goals identified for purposes of part 10 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act [this subpart], in the letters from the Secretary of Health and Human Services to the Chairman of the Committee on Health, Education, Labor, and Pensions of the Senate and the Chairman of the Committee on Energy and Commerce of the House of Representatives, as set forth in the Congressional Record.”
, , , provided that: